STAGE IVB PROSTATE CANCER AJCC V8

This study tests whether a special scan called PSMA PET can help pick men with castration-resistant prostate cancer that has spread to the bones who will get the most benefit from Ra-223 radiation therapy. Ra-223 is a radioactive drug that targets bone tumors. The trial enrolled …

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long men can stay on treatment and how well it controls the cancer. Par…

This early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…

This study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…

This study tests a combination of three drugs (apalutamide, abiraterone, and prednisone) given after chemotherapy to men with advanced prostate cancer that has spread and has not been treated before. The goal is to see if this hormone therapy can lower PSA levels more effectively…

This study tests whether adding rucaparib to standard enzalutamide helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo delays can…

This study looks at whether men with metastatic prostate cancer that has responded extremely well to hormone therapy can safely take a break from treatment. The goal is to see if pausing therapy allows their testosterone levels to return to normal, potentially improving quality o…

This study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and is no longer responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can…

This study tests whether adding the drug relugolix to standard radiation therapy can slow the spread of prostate cancer that has spread to a few other parts of the body. Relugolix lowers testosterone, which can help stop cancer growth. About 194 men with this type of prostate can…

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The goal…

This study is testing a two-part treatment for men whose prostate cancer has returned and spread to a few other places in the body. The treatment combines hormone-blocking drugs with very precise, high-dose radiation aimed directly at the cancer spots. The goal is to see if this …

This study is testing whether a combination of two drugs, niraparib/abiraterone and prednisone, can help control advanced prostate cancer that has spread and has a specific genetic mutation called SPOP. The treatment aims to stop cancer cells from repairing themselves and reduce …

This study tests a special PET scan called 68Ga-PSMA-11 to see if it can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer that has come back or spread will get this scan. The goal is to see if the scan changes how doctors plan treatment, s…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. Researchers will store and study these samples over time to learn how cancer changes and why some treatments stop working. The goal is to improve future …